Reboot Rx

Reboot Rx works to provide effective and affordable treatment options to cancer patients worldwide, including society’s most vulnerable, so they can live longer and better lives. Their proprietary AI technology rapidly identifies the most promising generic drugs for repurposing. Reboot Rx is bringing their first repurposed generic drug into the standard of care, which costs as little as $50 per year and could help hundreds of thousands of prostate cancer patients.

The Problem
10 million lives are lost to cancer each year. Patients urgently need affordable and effective treatment options, but the development of new drugs is an arduous and expensive process. Bringing just one new drug to market can take over a decade and cost $1 billion, with no guarantee of meaningful benefits: many new cancer drugs only extend survival by a few months yet cost patients over $100,000 annually. The financial toll is devastating, with around 40% of U.S. cancer patients exhausting their life savings within two years of diagnosis. There is a major opportunity to reduce the time and cost of creating new cancer treatments — while also prioritizing globally accessible therapies — through the repurposing of FDA-approved generic drugs. However, a fundamental market failure exists when it comes to repurposing generic drugs for new indications since pharmaceutical companies lack incentives to pursue this path, leaving potential life-saving treatments undeveloped and patients without access to affordable care.

The Solution
Reboot Rx envisions a future where cancer patients worldwide have access to effective, low-cost treatment options that help them live longer and better lives. Using their AI technology powered by machine learning and natural language processing, Reboot Rx accelerates the drug development process, identifying high-potential drug candidates for repurposing in weeks instead of years. Using this innovative approach, Reboot Rx’s team of AI and cancer experts identified promising generic drugs for prostate cancer, which have already been tested in clinical trials. They are now validating their findings with real-world evidence using electronic medical record data in partnership with the Veterans Health Administration (VA). Reboot Rx is also working to identify the most promising generic drugs for multiple other cancer types and will drive the adoption of generic drugs into the standard of care. While their work will create accessible treatment options for patients everywhere, those in resource-limited settings and those who face systemic health inequities will realize the most benefit from inexpensive and widely available repurposed generic drugs.